Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis

Mohssen Elalfy*, Yasser A. Wali, Mohamad Qari, Ghazi Al Damanhouri, Youssef Al-Tonbary, Dilek Yazman, Zakaria Al Hawsawi, Zeynep Karakas, Yurdanur Kilinc, M. Akif Yesilipek, Mohamed Badr, Usama Elsafy, Mostafa Salama, Yousryeia Abdel Rahman, Shebl Shebl, Anne Stilman, Noemi Toiber Temin, Fernando Tricta

*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلةمراجعة النظراء

14 اقتباسات (Scopus)

بصمة

أدرس بدقة موضوعات البحث “Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis'. فهما يشكلان معًا بصمة فريدة.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Agricultural and Biological Sciences